MedPath

AMITIZA

These highlights do not include all the information needed to use AMITIZA safely and effectively. See full prescribing information for AMITIZA.  AMITIZA (lubiprostone) capsule, gelatin coated for oral use Initial U.S. Approval: 2006

Approved
Approval ID

ca79dddc-3911-472b-bda7-a23351be09af

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 21, 2010

Manufacturers
FDA

STAT RX USA LLC

DUNS: 786036330

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LUBIPROSTONE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code16590-622
Application NumberNDA021908
Product Classification
M
Marketing Category
C73594
G
Generic Name
LUBIPROSTONE
Product Specifications
Route of AdministrationORAL
Effective DateJuly 21, 2010
FDA Product Classification

INGREDIENTS (7)

LUBIPROSTONEActive
Quantity: 8 ug in 1 1
Code: 7662KG2R6K
Classification: ACTIB
MEDIUM-CHAIN TRIGLYCERIDESInactive
Code: C9H2L21V7U
Classification: IACT
GELATINInactive
Code: 2G86QN327L
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
SORBITOLInactive
Code: 506T60A25R
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

AMITIZA - FDA Drug Approval Details